Signaling bias is critical for drug discovery as it forms a selection criterion for agonism. Measuring and quantifying signaling bias reveals which candidates emphasize therapeutically beneficial pathways, and which may be falsely characterized as equivalent by single-pathway assays. Drug discovery programs that do not consider investigating for signaling bias often fail to fully understand the distinction and risk candidate molecules from advancing along the pipeline.

GPCRs are no longer simple on/off switches. Discover how biased signaling and functional assays are reshaping GPCR drug discovery.

Dr. GPCR and Eurofins DiscoverX announce a strategic partnership to accelerate GPCR drug discovery by expanding access to validated, industry-standard cell-based assay platforms supporting pharmacological characterization, screening, and regulatory-compliant development.